XOMA Ltd.  (XOMA) Trade Now »     Rate XOMA  -  Discuss XOMA  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

XOMA: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Xoma moving XOMA

N/A

-6.50% in 116 days another bio looking to either break out or fall like a rock.  I think .75 is a good entry point but would watch it close. Continue reading »

XOMA good news... XOMA

80%

+6.58% in 78 days (closed on 08/14/09) Kraig Biocraft Laboratories, Inc. Gears Up to Double the Number of Genetic Insertions Performed and Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452. http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyI... Y M Continue reading »

XOMA...1,50 possible XOMA

80%

-3.34% in 13 hours (closed on 05/28/09) http://de.advfn.com/p.php?pid=staticchart&s=N%5EXOMA&p=0&t=16... http://de.advfn.com/p.php?pid=staticchart&s=NASDAQ%3AXOMA&p=5... http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=20... Continue reading »

Bullish on XOMA ... XOMA

62%

-14.95% in 178 days XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohn?s disease. Its products under ... Continue reading »

Xoma...$ 1,50 possible XOMA

80%

+14.36% in 41 days (closed on 05/06/09) http://www.xoma.com/ been difficult http://de.advfn.com/p.php?pid=staticchart&s=NASDAQ%3AXOMA&p=8... Continue reading »

From the Blogosphere

Friday's BioPlay: Xoma Ltd.

Shares of Xoma Ltd. (XOMA) closed up 38% Thursday, a gain analysts pinned on anticipation that the drug company will release positive data on its Type II diabetes treatment during a presentation this weekend. In research notes Thursday, analysts said the new Phase I data on the drug, XOMA 052, should be strong since Xoma released positive initial Phase I results for the treatment in September. The presentation will be made at the American Diabetes Association conference in New Orleans on Saturday. Continue reading »

Navigating the Minefield of Micro-Cap Biotechs

73%

The accompanying table includes 52 companies with market caps below the $150M minimum for inclusion in the ETF Innovators [ETFI] Emerging Bio-Pharma Index. While the performance is terrible with an average loss of nearly 50%, keep in mind that several buyouts in the out-of-favor micro-cap biotech space have been announced over the past year with 100%-plus takeover premiums, including under-the-radar names such as: 1.) SGX Pharma (SGXP) was acquired for $64M cash by Eli Lilly (LLY) for its cancer drug discovery platform 2.) Kosan Biosciences (KOSN) was acquired by Bristol-Myers (BMY) for its ... Continue reading »

Navigating the Minefield of Micro-Cap Biotechs

73%

The accompanying table includes 52 companies with market caps below the $150M minimum for inclusion in the ETF Innovators [ETFI] Emerging Bio-Pharma Index. While the performance is terrible with an average loss of nearly 50%, keep in mind that several buyouts in the out-of-favor micro-cap biotech space have been announced over the past year with 100%-plus takeover premiums, including under-the-radar names such as: 1.) SGX Pharma (SGXP) was acquired for $64M cash by Eli Lilly (LLY) for its cancer drug discovery platform 2.) Kosan Biosciences (KOSN) was acquired by Bristol-Myers (BMY) for its ... Continue reading »

XOMA Making the Right Moves XOMA

-66.22% in 546 days We believe Xoma's antibody discovery platform is starting to show signs of paying off, as both -052 and -629 could prove to be significant products. Continue reading »

Pre-Market Gappers

Gapping up: FSLR +31.6%, RTP +30.2%, NTWK +21.9%, AAUK +11.8%, XOMA +10.9%, ENER +9.1%, SRVY +8.8%, SPWR +8.6%, CTRP +8.6%, PBR +7.8%, YGE +7.8%, RMBS +6.8%, STP +7.6%, TSL +6.5%, RIO +6.3%, LDK +6.0%, CY +6.2%, GOLD +5.8%, MT +5.8%, NHY +5.3%, GFI +5.3%, FCX +5.2%, AA +4.8%, CDE +4.7%, URBN +3.6%... Gapping down: BID -8.1%, CSCO -6.8%, IVZ -3.7%, CRNT -3.1%, TS -1.8%, AIG -0.8%, BCS -0.8%. Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.